Posted by Michael Wonder on 30 Apr 2017
Schedule of Pharmaceutical Benefits - 1 May 2017
1 May 2017 - The 1 May 2017 issue of the Schedule of Pharmaceutical Benefits sees a number of new & revised listings.
The new & revised listings are:
- Blinatumomab (Blincyto) - new medicine
- Daclizumab (Daklinza) - new medicine
- Emtricitabine with rilpivirine hydrochloride and tenofovir alafenamide fumarate (Odefsey) - new combination product
- Fosaprepitant dimeglumine (Emend IV) - new formulation
- Netupitant with palonosetron hydrochloride (Akynzeo) - new indication
- Nintedanib esylate (Ofev)
